IN2015DN04087A - - Google Patents

Info

Publication number
IN2015DN04087A
IN2015DN04087A IN4087DEN2015A IN2015DN04087A IN 2015DN04087 A IN2015DN04087 A IN 2015DN04087A IN 4087DEN2015 A IN4087DEN2015 A IN 4087DEN2015A IN 2015DN04087 A IN2015DN04087 A IN 2015DN04087A
Authority
IN
India
Prior art keywords
jejuni
fragment
antibody
animal
methods
Prior art date
Application number
Other languages
English (en)
Inventor
Ghahroudi Mehdi Arbabi
Ali Riazi
Christine M Szymanski
Greg Hussack
Jamshid Tanha
Roger Mackenzie
Original Assignee
Nat Res Council Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Res Council Canada filed Critical Nat Res Council Canada
Publication of IN2015DN04087A publication Critical patent/IN2015DN04087A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/121—Helicobacter (G); Campylobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56922—Campylobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/205—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Campylobacter (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN4087DEN2015 2012-10-24 2013-10-24 IN2015DN04087A (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261718062P 2012-10-24 2012-10-24
PCT/CA2013/050806 WO2014063253A1 (en) 2012-10-24 2013-10-24 Anti-campylobacter jejuni antibodies and uses therefor

Publications (1)

Publication Number Publication Date
IN2015DN04087A true IN2015DN04087A (de) 2015-10-09

Family

ID=50543821

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4087DEN2015 IN2015DN04087A (de) 2012-10-24 2013-10-24

Country Status (12)

Country Link
US (2) US9926363B2 (de)
EP (1) EP2912059B1 (de)
JP (1) JP2015535224A (de)
KR (1) KR20150073211A (de)
CN (1) CN104870472A (de)
AU (1) AU2013334451A1 (de)
BR (1) BR112015009306A2 (de)
CA (1) CA2889398C (de)
IN (1) IN2015DN04087A (de)
MX (1) MX2015005304A (de)
PH (1) PH12015500929A1 (de)
WO (1) WO2014063253A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017199094A1 (en) 2016-05-20 2017-11-23 Novobind Livestock Therapeutics Inc. Antibodies against microorganisms and uses thereof
US12447202B2 (en) 2018-05-17 2025-10-21 Lumen Bioscience, Inc. Arthrospira platensis oral vaccine delivery platform
WO2020018586A1 (en) 2018-07-16 2020-01-23 Lumen Bioscience, Inc. Thermostable phycobiliproteins produced in spirulina
KR20210041557A (ko) * 2018-07-17 2021-04-15 후맙스 바이오메드 에스에이 캄필로박터 종에 대한 항체
WO2020099922A1 (en) 2018-11-13 2020-05-22 Novobind Livestock Therapeutics, Inc. Antibodies against disease causing agents of canines and felines and uses thereof
WO2021003456A1 (en) 2019-07-03 2021-01-07 Lumen Bioscience, Inc. Arthrospira platensis non-parenteral therapeutic delivery platform
CN110743009B (zh) * 2019-09-30 2023-08-01 广州医科大学附属第一医院 鞭毛蛋白抗体在制备防治泌尿系结石及肾损伤的药物中的应用
EP4404966A4 (de) * 2021-09-20 2025-12-03 Biomedit Inc Multivalente anti-campylobacter-antikörper und impfstoff
US20250136669A1 (en) * 2021-12-15 2025-05-01 Teikyo Heisei University Vhh antibody
CN118006561B (zh) * 2023-11-17 2024-07-30 瑞科盟(青岛)生物工程有限公司 一株高裂解率空肠弯曲杆菌噬菌体rdp-cj-22002、其杀菌组合物及其应用
CN120040584B (zh) * 2025-04-02 2025-07-22 北京新兴四寰生物技术有限公司 抗致病性弯曲菌的单克隆抗体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2202310T3 (es) 1991-12-13 2004-04-01 Xoma Corporation Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos.
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
AU3458299A (en) 1998-03-31 1999-10-18 United States Of America, As Represented By The Secretary Of Agriculture, The Monoclonal antibodies against (campylobacter jejuni) and (campylobacter coli) outer membrane antigens
CN100335900C (zh) 2001-11-30 2007-09-05 加拿大国家研究局 新的自组装分子
US8263078B2 (en) 2007-09-05 2012-09-11 Inotek Pharmaceuticals Corporation Antibodies against flagellin and uses thereof
US20100239583A1 (en) 2009-03-04 2010-09-23 Inotek Pharmaceuticals Corporation Antibodies against flagellin and uses thereof
CA2825552A1 (en) * 2011-01-28 2012-08-02 National Research Council Of Canada Engineering of immunoglobulin domains

Also Published As

Publication number Publication date
CN104870472A (zh) 2015-08-26
US9926363B2 (en) 2018-03-27
BR112015009306A2 (pt) 2017-08-22
EP2912059A1 (de) 2015-09-02
US10259864B2 (en) 2019-04-16
MX2015005304A (es) 2016-04-04
EP2912059B1 (de) 2019-08-14
WO2014063253A1 (en) 2014-05-01
US20180142000A1 (en) 2018-05-24
JP2015535224A (ja) 2015-12-10
AU2013334451A1 (en) 2015-06-04
CA2889398A1 (en) 2014-05-01
PH12015500929A1 (en) 2015-06-29
CA2889398C (en) 2023-08-01
US20150307597A1 (en) 2015-10-29
KR20150073211A (ko) 2015-06-30
EP2912059A4 (de) 2016-09-28

Similar Documents

Publication Publication Date Title
IN2015DN04087A (de)
PH12021550023A1 (en) Humanized anti-tau antibodies
PH12019500946A1 (en) Neutralizing anti-tl1a monoclonal antibodies
NZ594682A (en) Fully human antibodies specific to cadm1
NZ595235A (en) Compositions and methods for increasing muscle growth
NZ727024A (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
BR112013020500A8 (pt) anticorpo isolado, recombinante ou purificado
BR112016014284A2 (pt) anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo
GT201200318A (es) Anticuerpos hacia gdf8 humano
BR112018075737A2 (pt) anticorpo, composição, célula isolada, e, métodos para tratar câncer ou infecção em um paciente e para detectar expressão de pd-l1 em uma amostra.
MY198942A (en) Anti-tau antibodies and methods of use
DOP2011000404A (es) Polipeptidos y metodo de tratamiento
BR112012032778A2 (pt) "proteínas multiespecíficas e multivalentes"
UA123202C2 (uk) Антитіло до тау-білка і його застосування
UA113623C2 (uk) Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi)
EP2552961A4 (de) Humanisierte antikörper gegen il-25
ZA201806397B (en) Humanized anti clever-1 antibodies and their use
UA107836C2 (uk) Метод лікування хвороби альцгеймера
PE20141683A1 (es) Anticuerpos monoclonales especificos para el antigeno m2-1 del virus respiratorio sincicial (vrs)
WO2014143739A3 (en) Anti-alpha v beta 6 antibodies and uses thereof
MA40536A (fr) Anticorps anti-alpha v bêta 5 humanisés et leurs utilisations
UA117735C2 (uk) Склад витяжки з thymus serpyllum l. та його застосування
WO2012106669A3 (en) Foxc1 antibodies and methods of their use
BR112014029013A2 (pt) anticorpos de anti-ccl2 para tratamento de esclerodermia
WO2009149443A3 (en) A metal-citrate transporter antigen from streptomyces coelicolor and uses thereof